{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T10:26:16Z","timestamp":1782901576941,"version":"3.54.5"},"reference-count":114,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T00:00:00Z","timestamp":1762214400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["P30DK084567"],"award-info":[{"award-number":["P30DK084567"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01GM131374"],"award-info":[{"award-number":["R01GM131374"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01CA297778"],"award-info":[{"award-number":["R01CA297778"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01CA262794"],"award-info":[{"award-number":["R01CA262794"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P50 CA210964"],"award-info":[{"award-number":["P50 CA210964"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000871","name":"Mayo Clinic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008237","name":"Department of Surgery","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008237","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimica et Biophysica Acta (BBA) - Molecular Cell Research"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.bbamcr.2025.120081","type":"journal-article","created":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T15:30:53Z","timestamp":1762183853000},"page":"120081","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Frequent EPHA2 receptor mutations in cholangiocarcinoma disrupt receptor forward signaling supporting a tumor suppressor role"],"prefix":"10.1016","volume":"1873","author":[{"given":"Evodie","family":"Koutouan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Lillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayano","family":"Kabashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack W.","family":"Sample","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Carlson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rondell","family":"Graham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rory L.","family":"Smoot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena B.","family":"Pasquale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbamcr.2025.120081_bb0005","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/s41572-021-00300-2","article-title":"Cholangiocarcinoma","volume":"7","author":"Brindley","year":"2021","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.bbamcr.2025.120081_bb0010","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/s41575-022-00587-w","article-title":"Mutational signatures and processes in hepatobiliary cancers","volume":"19","author":"Zhuravleva","year":"2022","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.bbamcr.2025.120081_bb0015","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/s41571-023-00770-1","article-title":"Cholangiocarcinoma - novel biological insights and therapeutic strategies","volume":"20","author":"Ilyas","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.bbamcr.2025.120081_bb0020","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1053\/j.gastro.2013.10.013","article-title":"Pathogenesis, diagnosis, and management of cholangiocarcinoma","volume":"145","author":"Rizvi","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bbamcr.2025.120081_bb0025","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.gastha.2022.04.007","article-title":"Worldwide Incidence and Mortality of Biliary Tract Cancer","volume":"1","author":"Baria","year":"2022","journal-title":"Gastro Hep Adv."},{"key":"10.1016\/j.bbamcr.2025.120081_bb0030","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","article-title":"Cholangiocarcinoma 2020: the next horizon in mechanisms and management","volume":"17","author":"Banales","year":"2020","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.bbamcr.2025.120081_bb0035","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbamcr.2025.120081_bb0040","doi-asserted-by":"crossref","first-page":"4079","DOI":"10.1200\/JCO.2019.37.15_suppl.4079","article-title":"Pembrolizumab (pembro) for advanced biliary adenocarcinoma: Results from the KEYNOTE-028 (KN028) and KEYNOTE-158 (KN158) basket studies","volume":"37","author":"Bang","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbamcr.2025.120081_bb0045","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200015","article-title":"Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer","volume":"1","author":"Oh","year":"2022","journal-title":"NEJM Evidence"},{"key":"10.1016\/j.bbamcr.2025.120081_bb0050","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","article-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Kelley","year":"2023","journal-title":"Lancet"},{"issue":"1021-1031","key":"10.1016\/j.bbamcr.2025.120081_bb0055","article-title":"Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors","volume":"142","author":"Andersen","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bbamcr.2025.120081_bb0060","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1004135","article-title":"Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma","volume":"10","author":"Borad","year":"2014","journal-title":"PLoS Genet."},{"key":"10.1016\/j.bbamcr.2025.120081_bb0065","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/j.humpath.2014.03.014","article-title":"Fibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinoma","volume":"45","author":"Graham","year":"2014","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.bbamcr.2025.120081_bb0070","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1016\/j.celrep.2017.02.033","article-title":"Integrative genomic analysis of cholangiocarcinoma identifies distinct IDH-mutant molecular profiles","volume":"18","author":"Farshidfar","year":"2017","journal-title":"Cell Rep."},{"key":"10.1016\/j.bbamcr.2025.120081_bb0075","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","article-title":"Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bbamcr.2025.120081_bb0080","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1016\/S1470-2045(19)30733-8","article-title":"Second-line therapies in advanced biliary tract cancers","volume":"21","author":"Tella","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bbamcr.2025.120081_bb0085","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1002\/hep.27687","article-title":"IL-33 facilitates oncogene-induced cholangiocarcinoma in mice by an interleukin-6-sensitive mechanism","volume":"61","author":"Yamada","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.bbamcr.2025.120081_bb0090","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/bs.acr.2022.02.001","article-title":"Inflammatory pathways and cholangiocarcinoma risk mechanisms and prevention","volume":"156","author":"Cadamuro","year":"2022","journal-title":"Adv. Cancer Res."},{"key":"10.1016\/j.bbamcr.2025.120081_bb0095","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/path.5994","article-title":"Genetic alterations during the neoplastic cascade towards cholangiocarcinoma in primary sclerosing cholangitis","volume":"258","author":"Kamp","year":"2022","journal-title":"J. Pathol."},{"key":"10.1016\/j.bbamcr.2025.120081_bb0100","article-title":"Detecting Cholangiocarcinoma in the Setting of Primary Sclerosing Cholangitis: Is Biliary Tract Fluorescence In Situ Hybridization Helpful?","author":"Miller","year":"2024","journal-title":"Cytopathology"},{"key":"10.1016\/j.bbamcr.2025.120081_bb0105","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.jasc.2024.03.002","article-title":"Performance of fluorescence in situ hybridization in biliary brushings with equivocal cytology: an institutional experience","volume":"13","author":"Miller","year":"2024","journal-title":"J. Am. Soc. Cytopathol."},{"key":"10.1016\/j.bbamcr.2025.120081_bb0110","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/j.jhep.2024.02.008","article-title":"Syngeneic murine models with distinct immune microenvironments represent subsets of human intrahepatic cholangiocarcinoma","volume":"80","author":"Tomlinson","year":"2024","journal-title":"J. Hepatol."},{"key":"10.1016\/j.bbamcr.2025.120081_bb0115","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.jhep.2019.05.027","article-title":"Loss of Fbxw7 synergizes with activated Akt signaling to promote c-Myc dependent cholangiocarcinogenesis","volume":"71","author":"Wang","year":"2019","journal-title":"J. Hepatol."},{"key":"10.1016\/j.bbamcr.2025.120081_bb0120","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41568-023-00634-x","article-title":"Eph receptors and ephrins in cancer progression","volume":"24","author":"Pasquale","year":"2024","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bbamcr.2025.120081_bb0125","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ccr.2009.04.009","article-title":"EphA2 mediates ligand-dependent inhibition and ligand-independent promotion of cell migration and invasion via a reciprocal regulatory loop with Akt","volume":"16","author":"Miao","year":"2009","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bbamcr.2025.120081_bb0130","doi-asserted-by":"crossref","first-page":"7679","DOI":"10.1038\/ncomms8679","article-title":"Crucial roles of RSK in cell motility by catalysing serine phosphorylation of EphA2","volume":"6","author":"Zhou","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbamcr.2025.120081_bb0135","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1091\/mbc.e16-01-0048","article-title":"Protein kinase A can block EphA2 receptor-mediated cell repulsion by increasing EphA2 S897 phosphorylation","volume":"27","author":"Barquilla","year":"2016","journal-title":"Mol. Biol. Cell"},{"key":"10.1016\/j.bbamcr.2025.120081_bb0140","first-page":"6316","article-title":"cDNA cloning and characterization of eck, an epithelial cell receptor protein-tyrosine kinase in the eph\/elk family of protein kinases","volume":"10","author":"Lindberg","year":"1990","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.bbamcr.2025.120081_bb0145","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.biocel.2008.07.019","article-title":"Eph\/ephrin signaling in epithelial development and homeostasis","volume":"41","author":"Miao","year":"2009","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.bbamcr.2025.120081_bb0150","doi-asserted-by":"crossref","first-page":"44243","DOI":"10.1074\/jbc.M111.267047","article-title":"EphrinA1-EphA2 Signal Induces Compaction and Polarization of Madin-Darby Canine Kidney Cells by Inactivating Ezrin through Negative Regulation of RhoA","volume":"286","author":"Wakayama","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbamcr.2025.120081_bb0155","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.semcdb.2011.10.017","article-title":"Eph\/ephrin signaling in epidermal differentiation and disease","volume":"23","author":"Lin","year":"2012","journal-title":"Semin. Cell Dev. Biol."},{"key":"10.1016\/j.bbamcr.2025.120081_bb0160","doi-asserted-by":"crossref","first-page":"334","DOI":"10.3390\/genes4030334","article-title":"Roles of EphA2 in Development and Disease","volume":"4","author":"Park","year":"2013","journal-title":"Genes"},{"key":"10.1016\/j.bbamcr.2025.120081_bb0165","article-title":"Ephrin-Eph signaling: an important regulator of epithelial integrity and barrier function","volume":"2462855","author":"Liu","year":"2025","journal-title":"Tissue Barriers"},{"key":"10.1016\/j.bbamcr.2025.120081_bb0170","article-title":"Human cataract mutations in EPHA2 SAM domain alter receptor stability and function","volume":"7","author":"Park","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.bbamcr.2025.120081_bb0175","doi-asserted-by":"crossref","DOI":"10.1038\/s41388-021-01714-8","article-title":"Oncogenic functions and therapeutic targeting of EphA2 in cancer","author":"Wilson","year":"2021","journal-title":"Oncogene"},{"key":"10.1016\/j.bbamcr.2025.120081_bb0180","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/nrc2806","article-title":"Eph receptors and ephrins in cancer: bidirectional signalling and beyond","volume":"10","author":"Pasquale","year":"2010","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bbamcr.2025.120081_bb0185","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/nrd4175","article-title":"Therapeutic targeting of EPH receptors and their ligands","volume":"13","author":"Boyd","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bbamcr.2025.120081_bb0190","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1146\/annurev-pharmtox-011112-140226","article-title":"Eph receptors and ephrins: therapeutic opportunities","volume":"55","author":"Barquilla","year":"2015","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.bbamcr.2025.120081_bb0195","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1161\/CIRCULATIONAHA.116.026644","article-title":"EphA2 expression regulates inflammation and fibroproliferative remodeling in atherosclerosis","volume":"136","author":"Finney","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.bbamcr.2025.120081_bb0200","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1126\/science.aad3318","article-title":"Malaria parasites target the hepatocyte receptor EphA2 for successful host infection","volume":"350","author":"Kaushansky","year":"2015","journal-title":"Science"},{"issue":"423\u2013433","key":"10.1016\/j.bbamcr.2025.120081_bb0205","article-title":"EphA2 Is a Neutrophil Receptor for Candida albicans that Stimulates Antifungal Activity during Oropharyngeal Infection","volume":"28","author":"Swidergall","year":"2019","journal-title":"Cell Rep."},{"key":"10.1016\/j.bbamcr.2025.120081_bb0210","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1080\/14728222.2025.2500422","article-title":"Cataract-related mutations in EphA2: a survey of literature data and the relevance of the receptor Sam domain","volume":"29","author":"Vincenzi","year":"2025","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.bbamcr.2025.120081_bb0215","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1038\/ng.2273","article-title":"Exome sequencing of liver fluke-associated cholangiocarcinoma","volume":"44","author":"Ong","year":"2012","journal-title":"Nat. Genet."},{"key":"10.1016\/j.bbamcr.2025.120081_bb0220","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1038\/ng.2813","article-title":"Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas","volume":"45","author":"Jiao","year":"2013","journal-title":"Nat. Genet."},{"key":"10.1016\/j.bbamcr.2025.120081_bb0225","doi-asserted-by":"crossref","first-page":"5696","DOI":"10.1038\/ncomms6696","article-title":"Mutational landscape of intrahepatic cholangiocarcinoma","volume":"5","author":"Zou","year":"2014","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbamcr.2025.120081_bb0230","doi-asserted-by":"crossref","first-page":"6087","DOI":"10.1038\/ncomms7087","article-title":"Massive parallel sequencing uncovers actionable FGFR2-PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma","volume":"6","author":"Sia","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbamcr.2025.120081_bb0235","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1158\/2159-8290.CD-17-0368","article-title":"Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma","volume":"7","author":"Jusakul","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bbamcr.2025.120081_bb0240","doi-asserted-by":"crossref","first-page":"4264","DOI":"10.1038\/s41467-022-31780-9","article-title":"Landscape of somatic alterations in large-scale solid tumors from an Asian population","volume":"13","author":"Wu","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbamcr.2025.120081_bb0245","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkr407","article-title":"Predicting the functional impact of protein mutations: application to cancer genomics","volume":"39","author":"Reva","year":"2011","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.bbamcr.2025.120081_bb0250","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1038\/nprot.2009.86","article-title":"Predicting the effects of coding non\u2014Synonymous variants on protein function using the SIFT algorithm","volume":"4","author":"Kumar","year":"2009","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.bbamcr.2025.120081_bb0255","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/nmeth0410-248","article-title":"A method and server for predicting damaging missense mutations","volume":"7","author":"Adzhubei","year":"2010","journal-title":"Nat. Methods"},{"key":"10.1016\/j.bbamcr.2025.120081_bb0260","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/s41597-024-03327-8","article-title":"Analysis of AlphaMissense data in different protein groups and structural context","volume":"11","author":"Tordai","year":"2024","journal-title":"Sci. Data"},{"key":"10.1016\/j.bbamcr.2025.120081_bb0265","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/nature23306","article-title":"Integrative clinical genomics of metastatic cancer","volume":"548","author":"Robinson","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.bbamcr.2025.120081_bb0270","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2022.103870","article-title":"Ligands with different dimeric configurations potently activate the EphA2 receptor and reveal its potential for biased signaling","volume":"25","author":"Gomez-Soler","year":"2022","journal-title":"iScience"},{"key":"10.1016\/j.bbamcr.2025.120081_bb0275","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41594-021-00714-2","article-title":"Can AlphaFold2 predict the impact of missense mutations on structure?","volume":"29","author":"Buel","year":"2022","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.bbamcr.2025.120081_bb0280","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1038\/nsmb.1782","article-title":"An extracellular steric seeding mechanism for Eph-ephrin signaling platform assembly","volume":"17","author":"Seiradake","year":"2010","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.bbamcr.2025.120081_bb0285","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/embor.2009.91","article-title":"Ligand recognition by A-class Eph receptors: crystal structures of the EphA2 ligand-binding domain and the EphA2\/ephrin-A1 complex","volume":"10","author":"Himanen","year":"2009","journal-title":"EMBO Rep."},{"key":"10.1016\/j.bbamcr.2025.120081_bb0290","first-page":"71","article-title":"Constitutive activation of fibroblast growth factor receptor 3 by mutations responsible for the lethal skeletal dysplasia thanatophoric dysplasia type I","volume":"9","author":"d\u2019Avis","year":"1998","journal-title":"Cell Growth Differ."},{"key":"10.1016\/j.bbamcr.2025.120081_bb0295","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1359\/jbmr.2002.17.5.860","article-title":"Differential activation of cysteine-substitution mutants of fibroblast growth factor receptor 3 is determined by cysteine localization","volume":"17","author":"Adar","year":"2002","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bbamcr.2025.120081_bb0300","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1038\/onc.2014.106","article-title":"Glioma-specific Domain IV EGFR cysteine mutations promote ligand-induced covalent receptor dimerization and display enhanced sensitivity to dacomitinib in vivo","volume":"34","author":"Greenall","year":"2015","journal-title":"Oncogene"},{"key":"10.1016\/j.bbamcr.2025.120081_bb0305","doi-asserted-by":"crossref","first-page":"3903","DOI":"10.1016\/j.jmb.2016.08.026","article-title":"Pathogenic Cysteine Removal Mutations in FGFR Extracellular Domains Stabilize Receptor Dimers and Perturb the TM Dimer Structure","volume":"428","author":"Sarabipour","year":"2016","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.bbamcr.2025.120081_bb0310","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/0076-6879(91)00126-H","article-title":"Protein kinase catalytic domain sequence database: identification of conserved features of primary structure and classification of family members","volume":"200","author":"Hanks","year":"1991","journal-title":"Methods Enzymol."},{"key":"10.1016\/j.bbamcr.2025.120081_bb0315","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.tibs.2018.12.002","article-title":"Disordered Protein Kinase Regions in Regulation of Kinase Domain Cores","volume":"44","author":"Gogl","year":"2019","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.bbamcr.2025.120081_bb0320","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aan6776","article-title":"Truncation- and motif-based pan-cancer analysis reveals tumor-suppressing kinases","volume":"11","author":"Hudson","year":"2018","journal-title":"Sci. Signal."},{"key":"10.1016\/j.bbamcr.2025.120081_bb0325","doi-asserted-by":"crossref","first-page":"10860","DOI":"10.1073\/pnas.1004148107","article-title":"Architecture of Eph receptor clusters","volume":"107","author":"Himanen","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"1025-1034","key":"10.1016\/j.bbamcr.2025.120081_bb0330","article-title":"Interactions of the EphA2 Kinase Domain with PIPs in Membranes: Implications for Receptor Function","volume":"26","author":"Chavent","year":"2018","journal-title":"Structure"},{"key":"10.1016\/j.bbamcr.2025.120081_bb0335","doi-asserted-by":"crossref","first-page":"27271","DOI":"10.1074\/jbc.M115.676866","article-title":"EphA2 receptor unliganded dimers suppress EphA2 Pro-tumorigenic signaling","volume":"290","author":"Singh","year":"2015","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbamcr.2025.120081_bb0340","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1126\/science.adg5314","article-title":"Time-resolved live-cell spectroscopy reveals EphA2 multimeric assembly","volume":"382","author":"Shi","year":"2023","journal-title":"Science"},{"key":"10.1016\/j.bbamcr.2025.120081_bb0345","first-page":"G1060","article-title":"Regulation of intracellular pH by immortalized human intrahepatic biliary epithelial cell lines","volume":"266","author":"Grubman","year":"1994","journal-title":"Am. J. Phys."},{"key":"10.1016\/j.bbamcr.2025.120081_bb0350","doi-asserted-by":"crossref","first-page":"6470","DOI":"10.3748\/wjg.v13.i48.6470","article-title":"AKT and ERK1\/2 signaling in intrahepatic cholangiocarcinoma","volume":"13","author":"Schmitz","year":"2007","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.bbamcr.2025.120081_bb0355","doi-asserted-by":"crossref","DOI":"10.3390\/cells8101172","article-title":"Mitogen-Activated Protein Kinases (MAPKs) and Cholangiocarcinoma: The Missing Link","volume":"8","author":"Chen","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.bbamcr.2025.120081_bb0360","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.cgh.2012.09.009","article-title":"Classification, diagnosis, and management of cholangiocarcinoma","volume":"11","author":"Razumilava","year":"2013","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.bbamcr.2025.120081_bb0365","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1007\/s11605-017-3499-6","article-title":"Perioperative and Long-Term Outcome for Intrahepatic Cholangiocarcinoma: Impact of Major Versus Minor Hepatectomy","volume":"21","author":"Zhang","year":"2017","journal-title":"J. Gastrointest. Surg."},{"key":"10.1016\/j.bbamcr.2025.120081_bb0370","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.jamcollsurg.2017.12.011","article-title":"Preoperative Risk Score and Prediction of Long-Term Outcomes after Hepatectomy for Intrahepatic Cholangiocarcinoma","volume":"226","author":"Sasaki","year":"2018","journal-title":"J. Am. Coll. Surg."},{"key":"10.1016\/j.bbamcr.2025.120081_bb0375","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1038\/ng.3375","article-title":"Genomic spectra of biliary tract cancer","volume":"47","author":"Nakamura","year":"2015","journal-title":"Nat. Genet."},{"key":"10.1016\/j.bbamcr.2025.120081_bb0380","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.jhep.2020.03.007","article-title":"Molecular targeted therapies: Ready for \u201cprime time\u201d in biliary tract cancer","volume":"73","author":"Lamarca","year":"2020","journal-title":"J. Hepatol."},{"key":"10.1016\/j.bbamcr.2025.120081_bb0385","series-title":"Genomic Profiling of Biliary Tract Cancers: Comprehensive Assessment of Anatomic and Geographic Heterogeneity","author":"Tsilimigras","year":"2025"},{"key":"10.1016\/j.bbamcr.2025.120081_bb0390","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1126\/science.1235122","article-title":"Cancer genome landscapes","volume":"339","author":"Vogelstein","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.bbamcr.2025.120081_bb0395","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkz096","article-title":"DriverML: a machine learning algorithm for identifying driver genes in cancer sequencing studies","volume":"47","author":"Han","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.bbamcr.2025.120081_bb0400","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/s41568-020-0290-x","article-title":"A compendium of mutational cancer driver genes","volume":"20","author":"Martinez-Jimenez","year":"2020","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bbamcr.2025.120081_bb0405","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1038\/nrm1662","article-title":"Eph receptor signalling casts a wide net on cell behaviour","volume":"6","author":"Pasquale","year":"2005","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.bbamcr.2025.120081_bb0410","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/s41568-022-00481-2","article-title":"Nonsense-mediated RNA decay: an emerging modulator of malignancy","volume":"22","author":"Tan","year":"2022","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bbamcr.2025.120081_bb0415","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1038\/ng.3664","article-title":"The rules and impact of nonsense-mediated mRNA decay in human cancers","volume":"48","author":"Lindeboom","year":"2016","journal-title":"Nat. Genet."},{"key":"10.1016\/j.bbamcr.2025.120081_bb0420","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ctrv.2019.06.003","article-title":"FGFR2 genomic aberrations: Achilles heel in the management of advanced cholangiocarcinoma","volume":"78","author":"Mahipal","year":"2019","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.bbamcr.2025.120081_bb0425","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1002\/ijc.31979","article-title":"Mutated EPHA2 is a target for combating lymphatic metastasis in intrahepatic cholangiocarcinoma","volume":"144","author":"Sheng","year":"2019","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.bbamcr.2025.120081_bb0430","doi-asserted-by":"crossref","DOI":"10.7717\/peerj.12750","article-title":"Therapeutic targeting of ARID1A and PI3K\/AKT pathway alterations in cholangiocarcinoma","volume":"10","author":"Tessiri","year":"2022","journal-title":"PeerJ"},{"key":"10.1016\/j.bbamcr.2025.120081_bb0435","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1038\/s41467-022-30708-7","article-title":"The genomic landscape of cholangiocarcinoma reveals the disruption of post-transcriptional modifiers","volume":"13","author":"Zhang","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbamcr.2025.120081_bb0440","doi-asserted-by":"crossref","first-page":"9960","DOI":"10.1038\/s41467-024-54387-8","article-title":"Whole-exome sequencing reveals genomic landscape of intrahepatic cholangiocarcinoma and identifies SAV1 as a potential driver","volume":"15","author":"Zhou","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbamcr.2025.120081_bb0445","doi-asserted-by":"crossref","first-page":"3265","DOI":"10.3892\/mmr.2015.3865","article-title":"Hypoxia enhances cholangiocarcinoma invasion through activation of hepatocyte growth factor receptor and the extracellular signal-regulated kinase signaling pathway","volume":"12","author":"Vanichapol","year":"2015","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.bbamcr.2025.120081_bb0450","article-title":"Survey of tyrosine kinase signaling reveals ROS kinase fusions in human cholangiocarcinoma","volume":"6","author":"Gu","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.bbamcr.2025.120081_bb0455","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ctrv.2018.11.001","article-title":"Targeting the PI3K\/AKT\/mTOR pathway in biliary tract cancers: A review of current evidences and future perspectives","volume":"72","author":"Corti","year":"2019","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.bbamcr.2025.120081_bb0460","first-page":"2301","article-title":"EphA2 overexpression causes tumorigenesis of mammary epithelial cells","volume":"61","author":"Zelinski","year":"2001","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbamcr.2025.120081_bb0465","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ccr.2005.07.005","article-title":"A conditional feedback loop regulates Ras activity through EphA2","volume":"8","author":"Macrae","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bbamcr.2025.120081_bb0470","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1083\/jcb.201205176","article-title":"EphA2 cleavage by MT1-MMP triggers single cancer cell invasion via homotypic cell repulsion","volume":"201","author":"Sugiyama","year":"2013","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.bbamcr.2025.120081_bb0475","first-page":"629","article-title":"E-cadherin regulates the function of the EphA2 receptor tyrosine kinase","volume":"10","author":"Zantek","year":"1999","journal-title":"Cell Growth Differ."},{"key":"10.1016\/j.bbamcr.2025.120081_bb0480","article-title":"Missense mutations of the ephrin receptor EPHA1 associated with Alzheimer\u2019s disease disrupt receptor signaling functions","volume":"301","author":"Matsumoto","year":"2024","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbamcr.2025.120081_bb0485","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1002\/hep.26253","article-title":"Activation of mammalian target of rapamycin complex 1 (mTORC1) and Raf\/Pyk2 by growth factor-mediated Eph receptor 2 (EphA2) is required for cholangiocarcinoma growth and metastasis","volume":"57","author":"Cui","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.bbamcr.2025.120081_bb0490","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1158\/2159-8290.CD-17-0245","article-title":"New Horizons for Precision Medicine in Biliary Tract Cancers","volume":"7","author":"Valle","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bbamcr.2025.120081_bb0495","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/s41571-020-0357-3","article-title":"The SWI\/SNF complex in cancer - biology, biomarkers and therapy","volume":"17","author":"Mittal","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.bbamcr.2025.120081_bb0500","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1005748","article-title":"Genome-Wide Transcriptional Regulation Mediated by Biochemically Distinct SWI\/SNF Complexes","volume":"11","author":"Raab","year":"2015","journal-title":"PLoS Genet."},{"key":"10.1016\/j.bbamcr.2025.120081_bb0505","doi-asserted-by":"crossref","first-page":"512","DOI":"10.2353\/ajpath.2010.100168","article-title":"Cytoskeletal regulation of epithelial barrier function during inflammation","volume":"177","author":"Ivanov","year":"2010","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.bbamcr.2025.120081_bb0510","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0018128","article-title":"Lithocholic acid is an Eph-ephrin ligand interfering with Eph-kinase activation","volume":"6","author":"Giorgio","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.bbamcr.2025.120081_bb0515","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41389-019-0159-6","article-title":"EPHA2 mutations with oncogenic characteristics in squamous cell lung cancer and malignant pleural mesothelioma","volume":"8","author":"Tan","year":"2019","journal-title":"Oncogenesis"},{"key":"10.1016\/j.bbamcr.2025.120081_bb0520","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0042120","article-title":"A small molecule agonist of EphA2 receptor tyrosine kinase inhibits tumor cell migration in vitro and prostate cancer metastasis in vivo","volume":"7","author":"Petty","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.bbamcr.2025.120081_bb0525","doi-asserted-by":"crossref","first-page":"18575","DOI":"10.1074\/jbc.M109.075085","article-title":"EphA2 mutation in lung squamous cell carcinoma promotes increased cell survival, cell invasion, focal adhesions, and mammalian target of rapamycin activation","volume":"285","author":"Faoro","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbamcr.2025.120081_bb0530","doi-asserted-by":"crossref","first-page":"562","DOI":"10.6026\/97320630008562","article-title":"Screening and structural evaluation of deleterious non-synonymous SNPs of ePHA2 gene involved in susceptibility to cataract formation","volume":"8","author":"Masoodi","year":"2012","journal-title":"Bioinformation"},{"key":"10.1016\/j.bbamcr.2025.120081_bb0535","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0189881","article-title":"Germ-line and somatic EPHA2 coding variants in lens aging and cataract","volume":"12","author":"Bennett","year":"2017","journal-title":"PLoS ONE"},{"key":"10.1016\/j.bbamcr.2025.120081_bb0540","doi-asserted-by":"crossref","DOI":"10.3390\/ijms221910655","article-title":"Biallelic Variants in EPHA2 Identified in Three Large Inbred Families with Early-Onset Cataract","volume":"22","author":"Jarwar","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbamcr.2025.120081_bb0545","first-page":"511","article-title":"Autosomal recessive congenital cataract linked to EPHA2 in a consanguineous Pakistani family","volume":"16","author":"Kaul","year":"2010","journal-title":"Mol. Vis."},{"key":"10.1016\/j.bbamcr.2025.120081_bb0550","article-title":"Molecular characteristics and prognostic role of EPHA2 in human tumors via pan-cancer analysis","volume":"103","author":"Wang","year":"2024","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.bbamcr.2025.120081_bb0555","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","article-title":"The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data","volume":"2","author":"Cerami","year":"2012","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bbamcr.2025.120081_bb0560","doi-asserted-by":"crossref","first-page":"pl1","DOI":"10.1126\/scisignal.2004088","article-title":"Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal","volume":"6","author":"Gao","year":"2013","journal-title":"Sci. Signal."},{"key":"10.1016\/j.bbamcr.2025.120081_bb0565","doi-asserted-by":"crossref","first-page":"R41","DOI":"10.1186\/gb-2011-12-4-r41","article-title":"GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers","volume":"12","author":"Mermel","year":"2011","journal-title":"Genome Biol."},{"key":"10.1016\/j.bbamcr.2025.120081_bb0570","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s42003-018-0017-7","article-title":"The EphA2 receptor is activated through induction of distinct, ligand-dependent oligomeric structures","volume":"1","author":"Singh","year":"2018","journal-title":"Commun. Biol."}],"updated-by":[{"DOI":"10.1016\/j.bbamcr.2026.120139","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T00:00:00Z","timestamp":1773964800000}},{"DOI":"10.1016\/j.bbamcr.2026.120139","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000}}],"container-title":["Biochimica et Biophysica Acta (BBA) - Molecular Cell Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167488925001867?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167488925001867?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T20:44:11Z","timestamp":1781210651000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167488925001867"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":114,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S0167488925001867"],"URL":"https:\/\/doi.org\/10.1016\/j.bbamcr.2025.120081","relation":{},"ISSN":["0167-4889"],"issn-type":[{"value":"0167-4889","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Frequent EPHA2 receptor mutations in cholangiocarcinoma disrupt receptor forward signaling supporting a tumor suppressor role","name":"articletitle","label":"Article Title"},{"value":"Biochimica et Biophysica Acta (BBA) - Molecular Cell Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbamcr.2025.120081","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"120081"}}